logo
Black-tailed godwit joins NSW endangered species list as population dives

Black-tailed godwit joins NSW endangered species list as population dives

Scientists fear a remarkable migratory shorebird, which flies vast distances each year to reach Australia, will become extinct in the near future.
The black-tailed godwit is capable of reaching speeds of 95 kilometres per hour as it flies from as far as Siberia to Australian coastlines and inland locations such as the Macquarie Marshes in western New South Wales.
"Black-tailed godwits are a truly impressive bird, flying more than 10,000km twice a year to and from the Northern Hemisphere where they breed," UNSW ecologist Richard Kingsford said.
"Not many other birds in Australia fly such long distances."
Despite its strength and endurance, the bird was classed as endangered by the NSW Threatened Species Scientific Committee in late July.
Its estimated population met the "endangered" threshold of a 50 per cent to 80 per cent loss over three generations, or 23 years.
The committee also added four other birds to the state's threatened species list for the first time, determining the grey plover, ruddy turnstone, sharp-tailed sandpiper, and red knot birds all met the "vulnerable" threshold of a 30 to 50 per cent population decline.
All five species are migratory birds that travel to Australia through the East Asian–Australasian Flyway, an internationally recognised waterbird travelling route stretching from the Arctic Circle to New Zealand via East and South-East Asia.
Citing several population studies, the committee report noted the Australian numbers of the black-tailed godwit had fallen by a minimum of 52 per cent to as high as 77.5 per cent in 23 years.
It outlined how its habitat at stopovers on its long-haul journey are shrinking, competing with humans for the preferred coastal locations, and climate change and water management impacting on inland wetlands.
Professor Kingsford said it was a similar story for all the birds newly added to the list, with the challenges echoed across forests and estuaries.
"They're all indicative of the same problems — habitat loss and altered ecosystems — but also things like pollution, diseases and over-harvesting," he said.
Using an analogy of biodiversity as an aeroplane, he described how each declining species "rattled" the ecosystem.
"It's the equivalent of thinking about a plane that's stitched together with little rivets. If you start to lose those rivets, there's some point where that plane might fall out of the sky," Professor Kingsford said.
Professor Kingsford said the black-tailed godwit played an important role in the ecosystem, such as its contribution to improved water quality as a predator of worms, crustaceans and molluscs in mudflats and shallow waters.
He said while it faced an "imminent risk of extinction in the next 10 to 30 years", its decline along the way had also had a detrimental impact.
"We depend so much on what biodiversity gives us," Professor Kingsford said.
Professor Kingsford encouraged people to consider the environmental changes needed by directly addressing policy and to think longer term.
"The environment, things like climate change and pollution, and flooding in rivers, these are all major threats, and most of those are really a reflection of policies by governments and communities," he said.
"There's no more important way of influencing that than through the political process … not just for the next election cycle, but the next 100 years."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Health Check: Audeara strives to be ‘the next Cochlear' in affordable hearing collab
Health Check: Audeara strives to be ‘the next Cochlear' in affordable hearing collab

News.com.au

timean hour ago

  • News.com.au

Health Check: Audeara strives to be ‘the next Cochlear' in affordable hearing collab

Audeara and Ear Science Institute Australia will strive to develop a more affordable bone-conduction hearing device Auditor voices 'substantial doubt' over Universal Biosensors' viability Freeze a jolly good fellow: Brent Owens take over at cryopreserver Vitrafy Do we hear the next Cochlear (ASX:COH)? Hearing tech group Audeara has entered a project agreement with Ear Science Institute Australia (ESIA). This is to develop bone-conduction hearing tools for Australian high-need communities. ESIA contributes $100,000 and its considerable expertise. Bone conduction involves transmitting vibrations through the skull. This bypasses the eardrum and allows users to hear ambient sounds alongside audio. One target market is children who need help to hear in class, especially in regional areas. The WA-based ESIA has extensive experience in remote parts of the state – especially in indigenous communities – while remote teachers already use Audeara's headphones and buds. 'It's about finding a solution that can be delivered at scale, to enable access in cases where people don't have it,' Audeara CEO Dr James Fielding says. 'Also, if we can find a way that is a bit more consumer friendly then more people will use it." He says the problem is not necessarily hearing loss: the kids might have fluctuating hearing, speech processing disorder or an autism spectrum condition. 'It's really looking at how we can give kids the best chance of getting the information so they can learn from it.' The parties expect the project to kick off next month. Cochlear's Baha devices – as in bone-anchored hearing aid – cost around $10,000 locally. Strictly speaking, the $4 million market cap Audeara doesn't plan to challenge the $20 billion Cochlear any time soon. "But if we can be the next super partner of Cochlear that would appeal to me greatly,' Fielding says. Universal Biosensors is on the ropes Universal Biosensors (ASX:UBI) is fighting for its life. The company today reported half-year revenue of $2.2 million, down 11% and a $10.4 million loss compared with $7.23 million previously. (By dint of history, Universal is US domiciled and thus reports to the Securities and Exchange Commission.) Universal's June quarter deficit came in at $6.6 million, compared with a $3.72 million loss previously. The unflattering numbers prompted a stern 'substantial doubt' warning from auditor Price Waterhouse, which questions whether the company can continue as a going concern. 'The company has experienced recurring losses since its inception and has not generated any significant revenues,' says the notes to the accounts. 'The company has not generated significant revenues resulting in the net cash outflows and accumulated losses to date." The board forecasts "further cash outflows while growing the business over the coming period". Over time, Universal has accrued $113.6 million of losses. Management plans to fund the business by "growing revenue, pursuing joint venture or partnerships for its product portfolio, assets and raising cash through debt funding'. Related party loan to the rescue? On July 2, Universal signed a non-binding term sheet for a loan facility of up to $8.5 million, with substantial shareholder Viburnum Funds Pty Ltd. (Viburnum's Criag Coleman resigned from the board to avoid a conflict of interest.) The company said it also planned an equity raising. Subject to approval at a shareholder meeting on August 29, the 18-month facility has a 15% interest rate plus royalties. The facility is due to be finalised this Friday. Parlous financial state aside, Universal has applied its proprietary electro-chemical sensors in interesting ways. During the half, Universal derived most of its revenue from anti-coagulation human testing (Xprecia Prime) and a winery quality control tool (Sentia). The company has also developed a water pipe impurity sensor (Aquascout) and glucose monitoring for dogs and cats (Petrackr). Management says while no binding capital measures are in place, the company 'has successfully raised new equity capital in the past.' A change at the top no-one thaw coming A mere six months after the cryopreservation group's ASX listing, Vitrafy Life Sciences (ASX:VFY) CEO Kate Munnings will step down in favour of co-founder and deputy CEO Brent Owens. The former head of IVF provider Virtus Health, Munnings remains on the board. The company says its next stage would benefit from a 'leader with a deep knowledge of Vitrafy's cryopreservation technology, as well as the biotech sector'. As joint founder – and 2014 Masterchef winner to boot – we guess Owens ticks those boxes. Vitrafy is developing its cryopreservation hardware and Lifechain cloud-based management platform. This is for applications including cell and gene therapies, aquaculture (salmon breeding) and bovine reproduction. Vitrafy's US efforts centre on a collaboration with the US Army Institute of Surgical Research, which carried out a successful phase I study on blood platelet preservation. The project aims to improve the shelf-life of emergency blood platelets on the battlefield. More FDA turmoil … The turmoil at the US Food & Drug Administration (FDA) again has hit the headlines, with revelations of last-minute meddling in a drug-approval decision. On July 22, shares in the Nasdaq-listed Replimune group tumbled 77% after the agency issued a Complete Response Letter. This pertained to the company's proposed melanoma drug RP1. In effect, the FDA rejected the approval application in the late stages of the review process. According to the biotech newsletter Stat, internal FDA reviewers supported the therapy before a senior official stepped in. It's suggested that Replimune was caught in the crossfire of leadership changes, staff upheaval and internal dysfunction. The official was not biologics head Vinay Prasad. The Trump appointee last month was sent packing amid a shambolic episode involving the withdrawal and then reinstatement of Sarepta's Duchenne muscular dystrophy drug, Elevidys. America being America, both Replimune and Sarepta already are subject to shareholder class actions. … but Immutep's not complaining But our very own Immutep (ASX:IMM) has no complaints about the FDA's deportment. The oncology dug developer today said the agency delivered positive feedback on the company's proposed development of its first line treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Based on Immutep's clinical trial Tacti-003, the FDA concurs the company's drug candidate Efti should be evaluated in combo with the checkpoint inhibitor Keytruda. This paves way for a placebo-controlled registration trial, or a smaller single-arm study of 70 to 90 patients. Immutep chief Marc Voigt says the FDA's feedback highlights the unmet needs of the targeted group of HNSCC patients, who express low levels of the biomarker PD-L1. In the meantime, Immutep remains laser focused on its pivotal phase III lung cancer trial, Tacti-004.

Underrated animals: Short-finned eel
Underrated animals: Short-finned eel

ABC News

time8 hours ago

  • ABC News

Underrated animals: Short-finned eel

They can travel over land, climb walls and take down large prey. And that's all before the short-finned eel (Anguilla australis) makes it out into the ocean for their epic migration to mate. The location is so remote, scientists still don't know what happens while they're there. But then, as new baby eels, they need to swim thousands of kilometres back to the Australian mainland — and only one in every 10,000 hatchings make it. Cast your vote for Australia's most underrated animal here. Featuring: Dr Wayne Koster, Arthur Rylah Institute Production: Ann Jones, Presenter / Producer Ann Jones, Presenter / Producer Jacinta Bowler, Producer Jacinta Bowler, Producer Rebecca McLaren, Producer Rebecca McLaren, Producer Hamish Camilleri, Sound Engineer Hamish Camilleri, Sound Engineer Petria Ladgrove, Executive Producer Stream the brand-new series Dr Ann's Secret Lives on ABC iview.

Breakthrough for Rhythm's next-gen bowel test
Breakthrough for Rhythm's next-gen bowel test

The Australian

time15 hours ago

  • The Australian

Breakthrough for Rhythm's next-gen bowel test

ColoSTAT diagnostic performance consistent across colorectal cancer I to IV stages Performance meets clinical requirements for symptomatic patient testing use case Commercialisation steps underway as ColoSTAT kit transitioned to final production validation state Special Report: Rhythm Biosciences has announced that its second-generation ColoSTAT blood test detects colorectal cancer consistently across all stages of the disease, marking an important milestone as the company prepares for commercialisation later this year. Following completion of ColoSTAT Beta kit verification and validation announced in May, the Rhythm Biosciences (ASX:RHY) development team has received a batch of ColoSTAT kits produced by Quansys Biosciences using the final manufacturing process. As part of the validation process, blood samples from 300 patients, ranging from those without bowel cancer to those with stage I to IV of the disease, were tested to assess how well ColoSTAT works across all stages. While further studies will be completed, the results show the test is equally effective at detecting colorectal cancer at every stage, which is an important finding given its intended use for symptomatic patients who could have either early- or late-stage cancer tests often struggle to detect early-stage disease, so the fact that ColoSTAT performs well at this stage is seen as particularly important. The predictive cancer diagnostics technology company expects to finalise validation of the kits, algorithm, and instrumentation in the near term, ahead of a submission to the National Association of Testing Authorities (NATA) in Australia to include ColoSTAT in its ISO15189 laboratory test portfolio. NATA is Australia's primary accreditation body for laboratories and testing facilities. Commercial launch of ColoSTAT is planned for later in CY25, subject to NATA regulatory approval. Watch: CEO David Atkin's talks about early cancer detection. 'Establishing a clinically useful product' ColoSTAT is a simple, minimally invasive blood test designed for people unwilling or unable to undergo traditional screening methods for colorectal (bowel) cancer, the world's second leading cause of cancer deaths but highly treatable when detected early. The test identifies specific protein biomarkers in the blood that indicate the likelihood of colorectal cancer. The second-generation ColoSTAT blood test involved a redesign of the assay from a single-plex into a multiplex format with several objectives including: Simplify completion of the test for a routine laboratory Reduce turnaround times (TAT) Improve the quality and performance of the assay Reduce overall cost of goods for the assay Clinical advisor Dr Andy Feber said demonstrating performance across the full spectrum of neoplastic conditions was essential for a clinically useful product. 'Establishing ColoSTAT performance across the entire range of neoplastic conditions is an important requirement for a clinically useful product,' he said. 'I'm pleased to see this important milestone has been achieved.' This article was developed in collaboration with Rhythm Biosciences, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store